Pfizer Inc. $PFE Shares Newly Purchased by Advisors Asset Management Inc.

Pfizer logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Advisors Asset Management opened a new Pfizer position, buying 780,185 shares worth about $22.25 million in the third quarter. Institutional investors collectively own 68.36% of the company’s stock.
  • Analysts’ consensus rating is Hold, with an average price target of $30.32; six analysts rate the stock Buy, 14 Hold and two Sell.
  • Pfizer beat quarterly earnings and revenue estimates, reporting EPS of $0.87 and revenue of $16.58 billion. It declared a quarterly dividend of $0.43 per share, equivalent to a 6.3% yield at the article’s stated share price.
  • MarketBeat previews top five stocks to own in December.

Advisors Asset Management Inc. bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 780,185 shares of the biopharmaceutical company's stock, valued at approximately $22,251,000.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Bank of America Corp DE acquired a new stake in shares of Pfizer during the second quarter worth about $1,049,602,000. BlackRock Inc. increased its position in Pfizer by 6.3% in the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. Nykredit A S acquired a new position in Pfizer in the 2nd quarter valued at about $205,774,000. Assenagon Asset Management S.A. lifted its position in Pfizer by 96.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company's stock worth $286,609,000 after acquiring an additional 5,829,204 shares during the period. Finally, State Street Corp grew its stake in shares of Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on PFE shares. DZ Bank lowered Pfizer from a "buy" rating to a "hold" rating in a report on Friday, November 6th. UBS Group increased their price target on Pfizer from $27.00 to $30.00 and gave the stock a "neutral" rating in a report on Wednesday, November 4th. Cantor Fitzgerald lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Thursday, October 8th. Argus set a $40.00 price objective on shares of Pfizer in a research note on Wednesday, November 4th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 9th. Six research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus price target of $30.32.

Read Our Latest Analysis on Pfizer

Pfizer Stock Down 0.5%

Pfizer stock opened at $27.41 on Friday. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $31.44. The firm has a market capitalization of $156.25 billion, a price-to-earnings ratio of 9.46, a price-to-earnings-growth ratio of 1.90 and a beta of 0.31. The stock's fifty day moving average is $28.82 and its two-hundred day moving average is $27.03. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.10 and a current ratio of 1.42.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The company had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the prior year, the firm earned $0.87 earnings per share. The company's revenue for the quarter was down .4% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post 3.04 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.3%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's dividend payout ratio (DPR) is currently 245.71%.

Recent Pfizer Headlines

Investors following PFE have been watching these headlines:

  • Positive Sentiment: Pfizer secured exclusive rights outside Greater China to Starna Therapeutics’ three investigational in vivo CAR-T programs for autoimmune diseases. The agreement includes a $330 million upfront payment and up to $2.3 billion in potential milestones, adding a novel approach to Pfizer’s pipeline. Because the programs are preclinical, any commercial payoff is likely years away and uncertain. Article: Pfizer Secures Exclusive Rights To In Vivo CAR T Autoimmune Programs
  • Positive Sentiment: A recent analysis said Pfizer’s launched and acquired products grew 32% in the third quarter, suggesting newer medicines are gaining traction and could help offset pressure on older products and COVID-related revenue. Article: Pfizer's Launched and Acquired Drugs Grew 32% in Q3
  • Neutral Sentiment: Pfizer also reported updates to clinical studies, including an RSV booster study in older adults and a Phase 3 study of berobenatide. The entries provide no trial results, so they offer limited evidence of near-term commercial impact. Article: Pfizer Advances RSV Booster Study in Older Adults

Pfizer Company Profile

(Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company's products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

See Also

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines